

--44. An isolated keratinocyte growth factor (KGF) polypeptide comprising the amino acid sequence of Figure 7.

*Silva*  
*el*

45. An isolated keratinocyte growth factor (KGF) polypeptide comprising the amino acid sequence of Figure 7 or a segment thereof, wherein said polypeptide causes a greater stimulation in BALB/MK keratinocyte cells relative to NIH/3T3 fibroblasts than epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), acidic fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF), as measured by percent of maximal  $H^3$ -thymidine incorporation in each cell type.

*G*  
*1*

46. The polypeptide of claim 45, wherein said polypeptide that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than one-fold stimulation over background in NIH/3T3 fibroblasts

47. The polypeptide of claim 45, wherein an amount of said polypeptide that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than 1/50<sup>th</sup> of the maximal thymidine incorporation in NIH/3T3 cells stimulated by aFGF or bFGF.

48. The polypeptide of claim 45, wherein an amount of said polypeptide that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than 1/10<sup>th</sup> of the maximal thymidine incorporation in NIH/3T3 fibroblasts stimulated by EGF or TGF-alpha.

49. The polypeptide of claim 45, wherein the maximal thymidine incorporation in BALB/MK keratinocytes stimulated by said polypeptide obtained within the

concentration range of 0.1 to 3 nanomolar is at least twice that obtained with bFGF within the same concentration range.

50. A pharmaceutical composition comprising the polypeptide according to either claim 44 or 45 and a pharmaceutically acceptable carrier.

*Sell  
cl 2*

51. The polypeptide of claim 45, wherein the polypeptide is a segment of Figure 7 and is useful in the production of antibodies that selectively bind a KGF polypeptide having the amino acid sequence of Figure 7.

*Sell  
cl 2*

52. A pharmaceutical composition comprising the polypeptide according to claim 51 and a pharmaceutically acceptable carrier.

*Sell  
cl 3*

53. The polypeptide of claim 51, wherein the segment is a truncated polypeptide of Figure 7 which is N terminally truncated within the region of amino acids 32-78.

*G*

54. A pharmaceutical composition comprising the polypeptide according to claim 53 and a pharmaceutically acceptable carrier.

55. The polypeptide according to claim 53, wherein said polypeptide further comprises Met at the amino terminus.

56. The polypeptide according to claim 53, wherein said polypeptide is unglycosylated.

57. A pharmaceutical composition comprising the polypeptide according to claim 56 and a pharmaceutically acceptable carrier.

*Sills  
v14*

58. The polypeptide according to Claim 51, wherein said segment of Figure 7 comprises (a) a sufficient number of amino acids 32-64 to confer on the polypeptide said preferential mitogenic activity on cells of epithelial origin and (b) amino acids 65-189.

59. A pharmaceutical composition comprising the polypeptide according to Claim 58 and a pharmaceutically acceptable carrier.

60. The polypeptide according to Claim 58, wherein said polypeptide further comprises Met at the amino terminus.

*G*

61. The polypeptide according to Claim 58, wherein said polypeptide is unglycosylated.

62. A pharmaceutical composition comprising the polypeptide according to Claim 61 and a pharmaceutically acceptable carrier.

*Sills  
v15*

63. The polypeptide according to Claim 51, wherein said segment of Figure 7 comprises (a) a sufficient number of amino acids 32-64 to confer on the polypeptide said preferential mitogenic activity on cells of epithelial origin and (b) amino acids 65-194.

64. The polypeptide according to claim 63, wherein said polypeptide further comprises Met at the amino terminus.

65. The polypeptide according to Claim 63, wherein said polypeptide is unglycosylated.

66. A pharmaceutical composition comprising the polypeptide according to claim 64 and a pharmaceutically acceptable carrier.

*Sulls 26*  
67. The polypeptide according to Claim 51, wherein said segment of Figure 7 consists of (a) a sufficient number of amino acids 32-64 to confer on the polypeptide said preferential mitogenic activity on cells of epithelial origin and (b) amino acids 65-194.

*G*  
68. The polypeptide according to Claim 67, wherein said polypeptide is unglycosylated.

69. A pharmaceutical composition comprising the polypeptide according to claim 68 and a pharmaceutically acceptable carrier.

70. The polypeptide according to Claim 51, wherein said polypeptide comprises amino acids 32-194 of Figure 7.

*Sulls 27*  
71. A pharmaceutical composition comprising the polypeptide according to Claim 69 and a pharmaceutically acceptable carrier.